Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Transdermal System in Children with Moderate to Severe Pain
NCT01324570Phase 3Completed
- Sponsor
- Purdue Pharma
- Start
- Jul 2011
- Primary completion
- May 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of buprenorphine in pain, sponsored by Purdue Pharma. Primary endpoints: Number of Participants With Adverse Events up to 28 weeks, Apparent Clearance (CL/F) at Week 4 and 1 more. Started Jul 2011; status: completed.
02
Drugs
buprenorphine
03
Conditions
pain
Beyond the preview
Go deeper on NCT01324570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01324570.